Pyrimethamine-Sulphadoxine: How Great the Risk?

American Medical Association. Drug evaluations, 6th edn. Philadelphia: WB Saunders, 1986

Stahel E. , Druilhe P. , Gentilini M. Antagonism of chloroquine with other antimalarials. Trans R Soc Trop Med Hyg 1988; 82: 221

Rombo L. , Stenbeck J. , Lobel H.O. , Campbell C.C. , Papaioanou M. , Miller K.D. Does chloroquine contribute to the risk of serious adverse reactions to Fansidar? Lancet 1985; ii: 1298–9

Gottlieb M.S. , Knight S. , Mitsuyasu R. , Weisman J. , Roth M. , Young L.S. Prophylaxis of Pneumocystis carinii infection in AIDS with pyrimethamine-sulfadoxine. Lancet 1984; ii: 398–9

Hohlfeld P. , Daffos F. , Thulliez P. , Aufrant C. , Couvreur J. , MacAleese J. , Descombey D. , Forestier F. Fetal toxoplasmosis: outcome of pregnancy and infant follow-up after in utero treatment. J Pediatr 1989; 115: 765–9

McCabe R.E. , Oster S. Current recommendations and future prospects in the treatment of toxoplasmosis. Drugs 1989; 38: 973–87

Pape J.W. , Verdier R.I. , Johnson W.D. Treatment and prophylaxis of Isospora belli infection in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989; 320: 1044–7

Day NE and Working Group. Acquired immune deficiency syndrome in England and Wales to end 1993. Projections using data to end September 1989. Communicable Disease Report January 1990; 1–12

Hart L.L. , Middleton RK . Dias rounds. Drug information analysis service. Drug Intelligence and Clinical Pharmacology 1988; 22: 899–900

Coole L. , Wiselka M.J. , Nicholson K.G. Malaria prophylaxis in travellers from Britain. J Infect 1989; 18: 209–12

Phillips-Howard P.A. , Breeze E. , Lakin C. , Bradley D.J. Short-term travel to malarious areas: malaria risk in British residents. Travel Medicine International 1988; 6: 51–60

Steffen R. , Somaini B. Severe cutaneous adverse reactions to sulfadoxine-pyrimethamine in Switzerland. Lancet 1986; i: 610